HDAC9 and leukemia: Within this work, we aimed not only at the investigation of the HDAC class I novel inhibitor hydrazostat’s anticancer effectiveness in leukemia and neuroblastoma cell models, but also at the identification of the additional vulnerabilities of cancer cells tightly linked with HDACs.